107 related articles for article (PubMed ID: 14641143)
21. Comparison of outcomes after two standards-of-care reduced-intensity conditioning regimens and two different graft sources for allogeneic stem cell transplantation in adults with hematologic diseases: a single-center analysis.
Le Bourgeois A; Mohr C; Guillaume T; Delaunay J; Malard F; Loirat M; Peterlin P; Blin N; Dubruille V; Mahe B; Gastinne T; Le Gouill S; Moreau P; Mohty M; Planche L; Lode L; Bene MC; Chevallier P
Biol Blood Marrow Transplant; 2013 Jun; 19(6):934-9. PubMed ID: 23523970
[TBL] [Abstract][Full Text] [Related]
22. A conditioning platform based on fludarabine, busulfan, and 2 days of rabbit antithymocyte globulin results in promising results in patients undergoing allogeneic transplantation from both matched and mismatched unrelated donor.
Devillier R; Fürst S; Crocchiolo R; El-Cheikh J; Castagna L; Harbi S; Granata A; D'Incan E; Coso D; Chabannon C; Picard C; Etienne A; Calmels B; Schiano JM; Lemarie C; Stoppa AM; Bouabdallah R; Vey N; Blaise D
Am J Hematol; 2014 Jan; 89(1):83-7. PubMed ID: 24108528
[TBL] [Abstract][Full Text] [Related]
23. [The efficacy and safety of modified busulfan/fludarabine conditioning regimen in elderly or drug-intolerable patients with hematologic malignancies].
Wang FR; Huang XJ; Liu DH; Chen H; Wang Y; Tang FF; Sun YQ; Fu HX; Liu KY; Xu LP
Zhonghua Nei Ke Za Zhi; 2013 Dec; 52(12):1028-32. PubMed ID: 24503400
[TBL] [Abstract][Full Text] [Related]
24. Reduced intensity conditioning regimen followed by glycosylated G-CSF mobilized PBSCT in patients with solid tumors and malignant lymphomas.
Castagna L; Bertuzzi A; Nozza A; Siracusano L; Balzarotti M; Magagnoli M; Sarina B; Timofeeva I; Sinnone M; Grimoldi MG; Farè M; Santoro A
Bone Marrow Transplant; 2002 Aug; 30(4):207-14. PubMed ID: 12203136
[TBL] [Abstract][Full Text] [Related]
25. Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed hematologic malignancy following autologous stem cell transplantation.
Dey BR; McAfee S; Sackstein R; Colby C; Saidman S; Weymouth D; Poliquin C; Vanderklish J; Sachs DH; Sykes M; Spitzer TR
Biol Blood Marrow Transplant; 2001; 7(11):604-12. PubMed ID: 11760148
[TBL] [Abstract][Full Text] [Related]
26. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning.
Baron F; Lechanteur C; Willems E; Bruck F; Baudoux E; Seidel L; Vanbellinghen JF; Hafraoui K; Lejeune M; Gothot A; Fillet G; Beguin Y
Biol Blood Marrow Transplant; 2010 Jun; 16(6):838-47. PubMed ID: 20109568
[TBL] [Abstract][Full Text] [Related]
27. Successful engraftment with fludarabine, cyclophosphamide, and thymoglobulin conditioning regimen in unrelated transplantation for severe aplastic anemia: A phase II prospective multicenter study.
Kang HJ; Shin HY; Park JE; Chung NG; Cho B; Kim HK; Kim SY; Lee YH; Lim YT; Yoo KH; Sung KW; Koo HH; Im HJ; Seo JJ; Park SK; Ahn HS;
Biol Blood Marrow Transplant; 2010 Nov; 16(11):1582-8. PubMed ID: 20685256
[TBL] [Abstract][Full Text] [Related]
28. Post-Transplant Cyclophosphamide and Tacrolimus-Mycophenolate Mofetil Combination Prevents Graft-versus-Host Disease in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors.
Carnevale-Schianca F; Caravelli D; Gallo S; Coha V; D'Ambrosio L; Vassallo E; Fizzotti M; Nesi F; Gioeni L; Berger M; Polo A; Gammaitoni L; Becco P; Giraudo L; Mangioni M; Sangiolo D; Grignani G; Rota-Scalabrini D; Sottile A; Fagioli F; Aglietta M
Biol Blood Marrow Transplant; 2017 Mar; 23(3):459-466. PubMed ID: 28039079
[TBL] [Abstract][Full Text] [Related]
29. [Allogeneic stem cell transplantation following non-myeloablative conditioning: favorable results in 21 high risk patients with hematological malignancies treated in the Utrecht University Medical Center, the Netherlands].
Petersen EJ; Lokhorst HL; Verdonck LF
Ned Tijdschr Geneeskd; 2003 Nov; 147(47):2328-32. PubMed ID: 14669540
[TBL] [Abstract][Full Text] [Related]
30. [Comparison of intensified myeloablative conditioning regime without antithymocytic globulin (ATG) with myeloablative conditioning regime for single-unit unrelated umbilical cord blood transplantation in hematological malignancies].
Sun ZM; Liu HL; Wu Y; Geng LQ; Zheng CC; Tang BL; Zhu XY; Tong J; Wang XB; Ding KY; Wan X; Zhang L; Yao W; Zhang XH; Han YS; Yang HZ; Liu X; Zhu WW; Wu JS; Wang ZY
Zhonghua Yi Xue Za Zhi; 2016 Jul; 96(28):2214-9. PubMed ID: 27480651
[TBL] [Abstract][Full Text] [Related]
31. Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma.
Carella AM; Cavaliere M; Lerma E; Ferrara R; Tedeschi L; Romanelli A; Vinci M; Pinotti G; Lambelet P; Loni C; Verdiani S; De Stefano F; Valbonesi M; Corsetti MT
J Clin Oncol; 2000 Dec; 18(23):3918-24. PubMed ID: 11099321
[TBL] [Abstract][Full Text] [Related]
32. Stable engraftment after a conditioning regimen with fludarabine and melphalan for bone marrow transplantation from an unrelated donor.
Inamoto Y; Oba T; Miyamura K; Terakura S; Tsujimura A; Kuwatsuka Y; Tokunaga M; Kasai M; Murata M; Naoe T; Kodera Y
Int J Hematol; 2006 May; 83(4):356-62. PubMed ID: 16757439
[TBL] [Abstract][Full Text] [Related]
33. Calcineurin inhibitor--free graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide and brief-course sirolimus following reduced-intensity peripheral blood stem cell transplantation.
Solomon SR; Sanacore M; Zhang X; Brown S; Holland K; Morris LE; Bashey A
Biol Blood Marrow Transplant; 2014 Nov; 20(11):1828-34. PubMed ID: 25064745
[TBL] [Abstract][Full Text] [Related]
34. Pilot study of prophylactic ex vivo costimulated donor leukocyte infusion after reduced-intensity conditioned allogeneic stem cell transplantation.
Kumar AJ; Hexner EO; Frey NV; Luger SM; Loren AW; Reshef R; Boyer J; Smith J; Stadtmauer EA; Levine BL; June CH; Porter DL; Goldstein SC
Biol Blood Marrow Transplant; 2013 Jul; 19(7):1094-101. PubMed ID: 23635453
[TBL] [Abstract][Full Text] [Related]
35. Possibility of long-term remission in patients with advanced hematologic malignancies after reduced intensity conditioning regimen (RIC) and allogeneic stem cell transplantation.
Picardi A; Fabritiis Pd Pd; Cudillo L; Dentamaro T; Cupelli L; Ballatore G; Venditti A; Caravita T; Cristina Cox M; Catalano G; Amadori S
Hematol J; 2004; 5(1):24-31. PubMed ID: 14745426
[TBL] [Abstract][Full Text] [Related]
36. Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning.
Raiola AM; Dominietto A; Ghiso A; Di Grazia C; Lamparelli T; Gualandi F; Bregante S; Van Lint MT; Geroldi S; Luchetti S; Ballerini F; Miglino M; Varaldo R; Bacigalupo A
Biol Blood Marrow Transplant; 2013 Jan; 19(1):117-22. PubMed ID: 22940057
[TBL] [Abstract][Full Text] [Related]
37. Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation.
Couriel DR; Saliba RM; Giralt S; Khouri I; Andersson B; de Lima M; Hosing C; Anderlini P; Donato M; Cleary K; Gajewski J; Neumann J; Ippoliti C; Rondon G; Cohen A; Champlin R
Biol Blood Marrow Transplant; 2004 Mar; 10(3):178-85. PubMed ID: 14993883
[TBL] [Abstract][Full Text] [Related]
38. Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen: a pilot study in patients with refractory malignancies.
Pedrazzoli P; Da Prada GA; Giorgiani G; Schiavo R; Zambelli A; Giraldi E; Landonio G; Locatelli F; Siena S; Della Cuna GR
Cancer; 2002 May; 94(9):2409-15. PubMed ID: 12015766
[TBL] [Abstract][Full Text] [Related]
39. Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors.
Solomon SR; Sizemore CA; Sanacore M; Zhang X; Brown S; Holland HK; Morris LE; Bashey A
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1299-307. PubMed ID: 25797174
[TBL] [Abstract][Full Text] [Related]
40. Successful treatment of stem cell graft failure in pediatric patients using a submyeloablative regimen of campath-1H and fludarabine.
Ahmed N; Leung KS; Rosenblatt H; Bollard CM; Gottschalk S; Myers GD; Carrum G; Heslop HE; Brenner MK; Krance RA
Biol Blood Marrow Transplant; 2008 Nov; 14(11):1298-304. PubMed ID: 18940685
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
